
A phase II study of combination chemotherapy using docetaxel and irinotecan for TC-refractory or TC-resistant ovarian carcinomas (GOGO-OV2 study) and for primary clear or mucinous ovarian carcinomas (GOGO-OV3 Study)
Keywords: Ovarian cancer; Refractory; Resistant; Clear cell; Mucinous; Docetaxel; Irinotecan; TCCR, complete response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; RR, responsive rate; SD, stable disease; TC,